0 Replies
WORCESTER, Mass., Mar 31, 2010 (BUSINESS WIRE) –RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today reported financial results for the fourth quarter and year ended December 31, 2009. Contine Reading & Discuss→
0 Replies
WORCESTER, Mass., Mar 29, 2010 (BUSINESS WIRE) –RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that its financial results for the year ending 2009 will be released on Wednesday, March 31, 2010. Contine Reading & Discuss→
0 Replies
WORCESTER, Mass., Mar 25, 2010 (BUSINESS WIRE) — RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), announced that Pamela Pavco, Ph.D., Vice President of Pharmaceutical Development, will be presenting at the 3rd International Scar Club Meeting in... Contine Reading & Discuss→
0 Replies
Stories include:
FierceBiotech is the biotech industry's daily monitor, with a special focus on drug discovery and clinical trials. Keep up to speed with the latest biotechnology trends, breakthroughs and FDA approval news. Join 90,000+ biotechnology and pharma industry professionals who get FierceBiotech via daily email. Sign up today!
About... Contine Reading & Discuss→
0 Replies
Stories include:
FierceBiotech Research alerts lab research professionals on the latest scientific breakthroughs in drug discovery and development. Get your free weekly email briefing today!
Email address: *
About View Sample Privacy
A group of investigators at CalTech say they have successfully developed nanopolymers wrapped in a protein that can... Contine Reading & Discuss→
